Last reviewed 2026-05-18 · How we verify

Bevacizumab-Pfizer

Pfizer · Phase 3 active Small molecule

Bevacizumab-Pfizer is a VEGF inhibitor (monoclonal antibody) Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

Likelihood of approval

64.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
Big-pharma sponsor +3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Bevacizumab-Pfizer
Sponsor	Pfizer
Drug class	VEGF inhibitor (monoclonal antibody)
Target	VEGF (Vascular Endothelial Growth Factor)
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt tumor progression.

Approved indications

Metastatic colorectal cancer
Metastatic non-small cell lung cancer
Metastatic breast cancer
Recurrent glioblastoma
Metastatic renal cell carcinoma
Cervical cancer

Common side effects

Hypertension
Proteinuria
Hemorrhage (any grade)
Thrombotic events
Gastrointestinal perforation
Wound healing complications
Fatigue
Diarrhea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bevacizumab-Pfizer CI brief — competitive landscape report
Bevacizumab-Pfizer updates RSS · CI watch RSS
Pfizer portfolio CI

Frequently asked questions about Bevacizumab-Pfizer

What is Bevacizumab-Pfizer?

Bevacizumab-Pfizer is a VEGF inhibitor (monoclonal antibody) drug developed by Pfizer, indicated for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

How does Bevacizumab-Pfizer work?

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

What is Bevacizumab-Pfizer used for?

Bevacizumab-Pfizer is indicated for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer, Recurrent glioblastoma, Metastatic renal cell carcinoma.

Who makes Bevacizumab-Pfizer?

Bevacizumab-Pfizer is developed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What drug class is Bevacizumab-Pfizer in?

Bevacizumab-Pfizer belongs to the VEGF inhibitor (monoclonal antibody) class. See all VEGF inhibitor (monoclonal antibody) drugs at /class/vegf-inhibitor-monoclonal-antibody.

What development phase is Bevacizumab-Pfizer in?

Bevacizumab-Pfizer is in Phase 3.

What are the side effects of Bevacizumab-Pfizer?

Common side effects of Bevacizumab-Pfizer include Hypertension, Proteinuria, Hemorrhage (any grade), Thrombotic events, Gastrointestinal perforation, Wound healing complications.

What does Bevacizumab-Pfizer target?

Bevacizumab-Pfizer targets VEGF (Vascular Endothelial Growth Factor) and is a VEGF inhibitor (monoclonal antibody).

Drug class: All VEGF inhibitor (monoclonal antibody) drugs
Target: All drugs targeting VEGF (Vascular Endothelial Growth Factor)
Manufacturer: Pfizer — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Metastatic colorectal cancer
Indication: Drugs for Metastatic non-small cell lung cancer
Indication: Drugs for Metastatic breast cancer

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing